Additional data from Tokai’s galeterone Phase 1 study on CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone (TOK-001), in patients with castration-resistant prostate cancer (CRPC) will be highlighted in a poster presentation titled, "Phase I clinical trial of galeterone (TOK-001), a multifunctional anti-androgen and CYP17 inhibitor in castration resistant prostate cancer (CRPC)," abstract number 4665, on Sunday, June 3, 2012, 8:00 a.m. to 12:00 p.m. (CDT) at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).    

CRPC is an advanced, difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of androgen deprivation therapy. Galeterone is a proprietary small molecule, oral drug for the treatment of CRPC that disrupts the growth and survival of prostate cancer cells via a novel triple mechanism of action. The study findings, presented for the first time last month at the AACR Annual Meeting, show galeterone demonstrated efficacy and was well-tolerated in patients with CRPC. Additionally, preclinical data will be presented at ASCO elucidating the mechanisms of action of galeterone.

"While other approved and experimental CRPC therapies act via a single target, galeterone is highly differentiated as the only prostate cancer drug in development that combines three distinct mechanisms of action in one compound for a unique multi-target approach," said Martin D. Williams, president and chief executive officer, Tokai Pharmaceuticals. "Galeterone acts in three ways against the key driver of CRPC, androgen receptor signaling - it blocks ligand synthesis, blocks ligand receptor binding, and degrades the receptor itself. The efficacy observed in the galeterone ARMOR1 study, with both biochemical and radiological responses, combined with a favorable safety profile, support our Phase 2 clinical trial program to be initiated in the second half of 2012."


Tokai Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New technique could propel personalized cancer treatments